Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity
| Autor: | Biao Xu, Lina Kang, Yihai Liu, Mingyue Wu, Jiamin Xu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Sympathetic Nervous System Clinical chemistry Endocrinology Diabetes and Metabolism Clinical Biochemistry Empagliflozin Type 2 diabetes Lesion Renin-Angiotensin System chemistry.chemical_compound Mice Norepinephrine Endocrinology Glucosides Internal medicine medicine Sympathetic activity Oil Red O Animals Neuropeptide Y Benzhydryl Compounds Sodium-Glucose Transporter 2 Inhibitors lcsh:RC620-627 Inflammation Aldosterone Triglyceride business.industry Research Biochemistry (medical) Body Weight Neuropeptide Y receptor medicine.disease Atherosclerosis Lipids Renin‐angiotensin‐aldosterone system lcsh:Nutritional diseases. Deficiency diseases chemistry Disease Progression Sodium‐glucose cotransporter 2 inhibitor medicine.symptom business |
| Zdroj: | Lipids in Health and Disease, Vol 20, Iss 1, Pp 1-9 (2021) Lipids in Health and Disease |
| Popis: | BackgroundSeveral large clinical trials have confirmed the cardioprotective role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes. However, whether empagliflozin, as an SGLT2i, could alleviate atherosclerosis progression in non-diabetic states remain unknown.MethodsApoE-/- mice were fed a Western diet for 12 weeks to induce atherosclerosis. On the 7th week, a group of mice were treated with drinking water containing empagliflozin (10 mg/kg/day), while another group was given normal water. At the 12th week, the whole aortas of each group were harvested. Oil Red O, HE and Movat staining were performed for atherosclerotic lesion area and size. Mouse serum lipid profiles (total cholesterol [TC], triglyceride [TG], low-density lipoprotein-c [LDL], and high-density lipoprotein-c [HDL]), systemic inflammation levels (IL-1β, IL-6 and IL-10), renin-angiotensin-aldosterone system (RAAS) components and sympathetic activity (norepinephrine and neuropeptide Y) indicators were measured by ELISA.ResultsEmpagliflozin reduced the atherosclerotic lesion burden (-8.6 %,P = 0.004) at aortic root in ApoE-/- mice. In addition, empagliflozin decreased body weight (-3.27 g,P = 0.002), lipid profiles (TC: [-15.3 mmol/L,P = 0.011]; TG: [-2.4 mmol/L,P P = 0.010]), RAAS (renin [-9.3 ng/L,P = 0.047]; aldosterone [-16.7 ng/L,P P = 0.019]; neuropeptide Y [-8.8 ng/L,P = 0.002]). However, the anti-inflammatory effect of empagliflozin was not significantly evident.ConclusionsThe early atherosclerotic lesion size was less visible in empagliflozin-treated mice. Empagliflozin could decrease lipid profiles and sympathetic activity in atherosclerosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |